CD101 和 Tim3 在胃癌免疫微环境中的作用及其作为预后生物标志物的潜力
The role of CD101 and Tim3 in the immune microenvironment of gastric cancer and their potential as prognostic biomarkers.
本研究为未来探索GC的靶向治疗和个体化治疗策略奠定了基础。
DISEASE HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
The role of CD101 and Tim3 in the immune microenvironment of gastric cancer and their potential as prognostic biomarkers.
本研究为未来探索GC的靶向治疗和个体化治疗策略奠定了基础。
IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment.
白细胞介素17A(IL-17A)是IL-17细胞因子家族的主要成员,主要由辅助性T细胞17(Th17)产生。
αβ and γδ T-cell responses to Epstein-Barr Virus: insights in immunocompetence, immune failure and therapeutic augmentation in transplant patients.
EBV是一种人类γ疱疹病毒,可在免疫功能正常(单核细胞增多症、慢性疲劳综合征、胃癌、地方性Burkitt淋巴瘤、头颈部癌)和免疫抑制(移植后淋巴增殖性疾病、EBV相关软组织肿瘤)患者中引起多种疾病。
CAR-γδ T Cells Targeting Claudin18.2 Show Superior Cytotoxicity Against Solid Tumor Compared to Traditional CAR-αβ T Cells.
我们的结果表明,通用型 CAR-CLDN18.2- T 细胞有望用于治疗 CLDN18.2 阳性实体瘤,并为开发更通用的 CAR-T 细胞肿瘤免疫治疗策略提供了启示。
FAT4 Mutation is Related to Tumor Mutation Burden and Favorable Prognosis in Gastric Cancer.
FAT4突变与GC中的TMB及良好预后相关,可能成为GC患者免疫治疗的有用生物标志物。
Identification of a six-gene signature to predict survival and immunotherapy effectiveness of gastric cancer.
我们发现了一个6基因特征来预测GC患者的OS。这一风险特征被证明是指导临床实践的有价值的临床预测工具。
CD4(-)/CD8(-) double-negative tumor-infiltrating lymphocytes expanded from solid tumor tissue suppress the proliferation of tumor cells in an MHC-inde
胃癌来源的DN-TIL能够在体外和体内靶向肿瘤细胞。DN-TIL有潜力作为实体癌的过继细胞疗法,兼具DNT和TIL的优势。
Identification of 8-gene risk prediction signature associated with NOTCH1 in stomach adenocarcinoma based on bioinformatics analysis.
NOTCH1 可能是胃腺癌的潜在靶点。
MEMBER ACCOUNT
登录成功会直接打开下一页。